4-(8-Quinolinylsulfonylamino)benzoic acid is an intermediate typically used in the preparation of Mitapivat (AG-348), an activator of a pyruvate kinase PKM2 for the treatment of Pyruvate Kinase (PK) Deficiency.
AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency. 
The design of potent HIV-1 integrase inhibitors by a combined approach of structure-based virtual screening and molecular dynamics simulation. 
AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes. 
 C.Kung, et al, Blood, 2017, 130(11), pp 1347-1356.
 A.S.Samorlu, et al, J. Biomol. Struct. Dyn., 2019, 37(17), pp 4644-4650.
 M.A.E.Rab, et al, Haematologica, 2020, DOI: 10.3324/haematol.2019.238865.
NONH for all modes of transport
1. Product Specification
2. Safety Data Sheet
Please inquire for pricing and availability of this product by writing email email@example.com.